An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the pharmacokinetics of intravenous ganciclovir in children (ages 3 months - 12
years). To determine the safety and tolerance of a 2 to 3 week induction course of
ganciclovir IV in immunocompromised children receiving treatment for life- or
sight-threatening cytomegalovirus infections.